Journal Article Summary
The article investigates the effects of different formulations of combined oral contraceptives (COCs) on blood clotting factors, which are important for understanding the risk of thrombosis. This topic is significant because hormonal contraceptives are widely used, and their association with increased thrombotic risk can have serious health implications for women. The study specifically compares the impact of contraceptives containing varying doses of estrogen and different progestins, particularly drospirenone and levonorgestrel, on hemostatic variables in young women.
In this cross-sectional study, researchers analyzed 70 healthy women aged 18 to 30, some of whom were using COCs while others were not. They measured various blood parameters related to coagulation, including prothrombin time, activated partial thromboplastin time, fibrinogen levels, and several proteins involved in blood clotting. The findings revealed that the contraceptive containing the lowest dose of estrogen and drospirenone (DRSP/20EE) led to significant changes in several hemostatic parameters, indicating a state of hypercoagulation. In contrast, the contraceptives containing levonorgestrel and higher doses of drospirenone also caused changes but to a lesser extent.
The study has limitations, including a small sample size and challenges in recruiting participants who met specific criteria. These factors may affect the reliability of the results, which should be interpreted as preliminary. Patients using hormonal contraceptives should discuss their individual risks and benefits with healthcare professionals, especially regarding the potential for increased thrombotic events associated with certain formulations. It is essential for women to be informed about these risks to make educated decisions about their contraceptive options.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Stocco Bianca, Fumagalli Helen F., Franceschini Silvio A., Martinez Edson Z., Marzocchi-Machado Cleni M., de Sá Marcos Felipe S., Toloi Maria Regina T.. Comparative Study of the Effects of Combined Oral Contraceptives in Hemostatic Variables. Medicine 2015. DOI: 10.1097/MD.0000000000000385. PMID: 25634167. PMCID: PMC4602984.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive --- Perrigo
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive --- Perrigo is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
